Mineralys Therapeutics, Inc.
NasdaqGS MLYS
Mineralys Therapeutics, Inc. Share Price on January 14, 2025: USD 9.12
Mineralys Therapeutics, Inc. Share Price is USD 9.12 on January 14, 2025, a 5.07% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.
-
Mineralys Therapeutics, Inc. 52-week high Share Price is USD 16.15 on February 26, 2024, which is 77.08% above the current Share Price.
-
Mineralys Therapeutics, Inc. 52-week low Share Price is USD 8.27 on January 18, 2024, which is -9.32% below the current Share Price.
-
Mineralys Therapeutics, Inc. average Share Price for the last 52 weeks is USD 12.62.
Key data
| Date | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) |
|---|
Market news
Loading...
NasdaqGS: MLYS
| CEO | Mr. Jon Congleton |
| IPO Date | Feb. 10, 2023 |
| Location | United States |
| Headquarters | 150 N. Radnor Chester Rd. |
| Employees | 28 |
| Sector | Health Care |
| Industries | |
Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email